Literature DB >> 11158765

Comparative toxicities and pharmacokinetics of intrathecal lipid (amphotericin B colloidal dispersion) and conventional deoxycholate formulations of amphotericin B in rabbits.

K V Clemons1, R A Sobel, P L Williams, D A Stevens.   

Abstract

The lipid formulation of amphotericin B, Amphotec (ABCD), has not been used intrathecally. After a single intrathecal dose or after four doses, conventionally formulated deoxycholate amphotericin B (AMB) (Fungizone) resulted in higher levels of amphotericin B in the cerebrospinal fluid of rabbits than did ABCD. Clinically and histologically, ABCD was about threefold less toxic than AMB after a single dose and 3- to 30-fold less toxic after multiple dosing. These data are encouraging for the potential use of ABCD as an intrathecal treatment.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11158765      PMCID： PMC90337          DOI： 10.1128/AAC.45.2.612-615.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  18 in total

1.  Single-dose pharmacokinetics and tolerance of a cholesteryl sulfate complex of amphotericin B administered to healthy volunteers.

Authors:  S W Sanders; K N Buchi; M S Goddard; J K Lang; K G Tolman
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

Review 2.  Amphotericin B: 30 years of clinical experience.

Authors:  H A Gallis; R H Drew; W W Pickard
Journal:  Rev Infect Dis       Date:  1990 Mar-Apr

3.  Dose-dependent antifungal activity and nephrotoxicity of amphotericin B colloidal dispersion in experimental pulmonary aspergillosis.

Authors:  M C Allende; J W Lee; P Francis; K Garrett; H Dollenberg; J Berenguer; C A Lyman; P A Pizzo; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

4.  Synergy between cilofungin and amphotericin B in a murine model of candidiasis.

Authors:  L H Hanson; A M Perlman; K V Clemons; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

5.  Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rats.

Authors:  R M Fielding; P C Smith; L H Wang; J Porter; L S Guo
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

6.  The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses.

Authors:  B A Oppenheim; R Herbrecht; S Kusne
Journal:  Clin Infect Dis       Date:  1995-11       Impact factor: 9.079

7.  Comparative neurotoxicities of amphotericin B and its mono-methyl ester derivative in rats.

Authors:  K R Reuhl; M Vapiwala; M T Ryzlak; C P Schaffner
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

8.  Is it ever safe to stop azole therapy for Coccidioides immitis meningitis?

Authors:  D H Dewsnup; J N Galgiani; J R Graybill; M Diaz; A Rendon; G A Cloud; D A Stevens
Journal:  Ann Intern Med       Date:  1996-02-01       Impact factor: 25.391

9.  Efficacy and safety of amphotericin B colloidal dispersion compared with those of amphotericin B deoxycholate suspension for treatment of disseminated murine cryptococcosis.

Authors:  J S Hostetler; K V Clemons; L H Hanson; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

10.  Treatment of mycoses with itraconazole.

Authors:  R M Tucker; P L Williams; E G Arathoon; D A Stevens
Journal:  Ann N Y Acad Sci       Date:  1988       Impact factor: 5.691
View more
  6 in total

1.  Cryptococcal meningitis in patients with autoimmune hemolytic anemia.

Authors:  YaLi Yang; Junjun Sang; Weihua Pan; Lin Du; Wanqing Liao; Jianghan Chen; Yuanjie Zhu
Journal:  Mycopathologia       Date:  2014-06-21       Impact factor: 2.574

2.  Comparative pharmacokinetics of continuous and conventional intrathecal amphotericin B in rabbits.

Authors:  Min Fang; Tian Ming Lü; An De Ma; Li Wang; Guo Liang Li; Ai Zhu Qiu; Zhi Yong Pan; Yuan Yuan Wang; Xiao Jia Liu
Journal:  Antimicrob Agents Chemother       Date:  2012-07-30       Impact factor: 5.191

3.  Comparative efficacies of four amphotericin B formulations--Fungizone, amphotec (Amphocil), AmBisome, and Abelcet--against systemic murine aspergillosis.

Authors:  Karl V Clemons; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

4.  Safety and tolerability of intrathecal liposomal amphotericin B (AmBisome) for cryptococcal meningitis: a retrospective study in HIV-infected patients.

Authors:  Gerardo Alvarez-Uria; Manoranjan Midde; Jayaram Battula; Himachandra N B Pujari
Journal:  Ther Adv Infect Dis       Date:  2018-06-12

5.  Short-Course Induction Treatment with Intrathecal Amphotericin B Lipid Emulsion for HIV Infected Patients with Cryptococcal Meningitis.

Authors:  Gerardo Alvarez-Uria; Manoranjan Midde; Raghavakalyan Pakam; Pradeep Sukumar Yalla; Praveen Kumar Naik; Raghuprakash Reddy
Journal:  J Trop Med       Date:  2015-09-10

Review 6.  Animal models: an important tool in mycology.

Authors:  Javier Capilla; Karl V Clemons; David A Stevens
Journal:  Med Mycol       Date:  2007-12       Impact factor: 4.076
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.